<p>Annexon, Inc.（纳斯达克代码：ANNX - 免费报告）- HC Wainwright 的股票研究人员在 5 月 8 日星期五向客户和投资者发布的研究报告中提高了对 Annexon 2030 财年的每股收益（EPS）预期。HC Wainwright 分析师 A. Ghosh 现在预计该公司将发布每股收益 0.56 美元，高于之前的 0.43 美元预期。市场普遍预期 Annexon 当前全年的每股收益为（1.13 美元）。</p>
<p>其他几位研究分析师最近也对该股票发表了看法。Chardan Capital 在 3 月 20 日星期五的报告中重申了对 Annexon 的 “买入” 评级，并给出了 16.00 美元的目标价。Cantor Fitzgerald 在 1 月 14 日星期三的研究报告中重申了对 Annexon 的 “增持” 评级。Weiss Ratings 在 4 月 20 日星期一的研究报告中重申了对 Annexon 的 “卖出（d-）” 评级。最后，Wall Street Zen 在周六的报告中将 Annexon 的评级从 “卖出” 上调至 “持有”。五位股票研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，共识目标价为 17.00 美元。</p>
<p><strong>查看我们关于 Annexon 的最新研究报告</strong></p>
<h2>Annexon 价格表现</h2>
<p>纳斯达克 ANNX 周一开盘价为 5.69 美元。该公司的 50 日简单移动平均为 5.69 美元，200 日简单移动平均为 5.08 美元。Annexon 的一年低点为 1.60 美元，一年高点为 7.18 美元。该公司的市值为 9.3225 亿美元，市盈率为 -4.66，贝塔值为 1.22。</p>
<p>Annexon（纳斯达克：ANNX - 获取免费报告）最近于 5 月 7 日星期四发布了季度财报。该公司报告的每股收益为（0.23 美元），超过了市场普遍预期的（0.30 美元）7 美分。</p>
<h2>Annexon 内部交易</h2>
<p>在相关消息中，执行副总裁 Michael Overdorf 于 2 月 18 日星期三出售了 6,225 股该股票。该股票的平均售价为 5.10 美元，总价值为 31,747.50 美元。交易后，该执行副总裁持有 124,464 股公司股票，价值 634,766.40 美元。这代表其持股比例减少了 4.76%。该交易已在证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站获取。此外，首席财务官 Jennifer Lew 于 2 月 18 日星期三出售了 7,851 股公司的股票。该股票的平均售价为 5.11 美元，总价值为 40,118.61 美元。出售后，首席财务官持有 113,765 股公司股票，价值 581,339.15 美元。该交易使其持股比例减少了 6.46%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去的九十天里，内部人士共出售了价值 165,973 美元的 32,513 股公司股票。公司内部人士持有公司股票的 12.67%。</p>
<h2>对 Annexon 的对冲基金看法</h2>
<p>一些对冲基金和其他机构投资者最近修改了对 ANNX 的持股。AQR Capital Management LLC 在第一季度将其在 Annexon 的持股增加了 122.6%。AQR Capital Management LLC 目前持有 73,790 股公司股票，价值 142,000 美元，此前在上个季度购买了 40,637 股。Jane Street Group LLC 在第一季度将其在 Annexon 的持股增加了 8.2%。Jane Street Group LLC 目前持有 99,924 股公司股票，价值 193,000 美元，此前在上个季度购买了 7,553 股。Acadian Asset Management LLC 在第一季度将其在 Annexon 的持股增加了 31.1%。Acadian Asset Management LLC 目前持有 203,990 股公司股票，价值 393,000 美元，此前在上个季度购买了 48,345 股。Geode Capital Management LLC 在第二季度将其在 Annexon 的持股增加了 1.8%。Geode Capital Management LLC 目前持有 2,284,773 股公司股票，价值 5,484,000 美元，此前在上个季度购买了 39,763 股。最后，American Century Companies Inc. 在第二季度将其在 Annexon 的持股增加了 6.6%。American Century Companies Inc. 目前持有 211,195 股公司股票，价值 507,000 美元，此前在上个季度购买了 13,001 股。</p>
<h2>Annexon 公司简介</h2>
<p>（获取免费报告）</p>
<p>Annexon Inc 是一家临床阶段的生物技术公司，专注于针对神经退行性和神经免疫疾病患者的补体靶向疗法的发现和开发。该公司的研究平台以抑制 C1 复合物为中心，C1 复合物是经典补体途径的关键启动因子，涉及多种罕见且危及生命的疾病。通过选择性地靶向上游补体激活，Annexon 旨在防止异常的免疫介导损伤，这种损伤是吉兰 - 巴雷综合症（GBS）和自身免疫性神经病等疾病的特征。</p>
<p>Annexon 的管线核心是 ANX005，这是一种针对 C1q 亚单位的人源化单克隆抗体，目前正在进行急性 GBS 和慢性神经退行性疾病的二期临床试验。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票超过 Annexon</li>
<li>超越 NVIDIA：强劲势头的 Picks-and-Shovels AI 投资</li>
<li>量子财报季正在升温——关注两大主要参与者</li>
<li>Flutter 在财报后看到提升，FanDuel 显示复苏迹象</li>
<li>3 只医疗保健股票将从一项重大法案中受益</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5OWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5OWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Annexon 吗？</h2>
<p>在考虑 Annexon 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Annexon 并不在名单上。</p>
<p>虽然 Annexon 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ANNX

纳斯达克生物科技指数 ETF - iShares Nasdaq

2 倍做多纳斯达克生物技术 ETF - ProShares

<p>HC Wainwright 将 Annexon, Inc. 的 2030 财年每股收益预期从 $0.43 上调至 $0.56，而当前年度的共识预期为每股 ($1.13)。该股票获得了分析师的混合评级，其中包括五个买入评级、一个持有评级和一个卖出评级。Annexon 的股票开盘价为 $5.69，市值为 9.3225 亿美元。近期内部人士的出售和机构投资也引起了关注，表明该股票的交易活跃。该公司专注于开发针对神经退行性疾病的疗法</p>

<p>Annexon, Inc. (NASDAQ:ANNX - Free Report) - Equities researchers at HC Wainwright increased their FY2030 EPS estimates for Annexon in a research report issued to clients and investors on Friday, May 8th. HC Wainwright analyst A. Ghosh now anticipates that the company will post earnings per share of $0.56 for the year, up from their prior estimate of $0.43. The consensus estimate for Annexon's current full-year earnings is ($1.13) per share.</p>
<div class="lb-trans"><p>Annexon, Inc.（纳斯达克代码：ANNX - 免费报告）- HC Wainwright 的股票研究人员在 5 月 8 日星期五向客户和投资者发布的研究报告中提高了对 Annexon 2030 财年的每股收益（EPS）预期。HC Wainwright 分析师 A. Ghosh 现在预计该公司将发布每股收益 0.56 美元，高于之前的 0.43 美元预期。市场普遍预期 Annexon 当前全年的每股收益为（1.13 美元）。</p>
</div><p>Several other research analysts have also recently weighed in on the stock. Chardan Capital reaffirmed a &#34;buy&#34; rating and issued a $16.00 price target on shares of Annexon in a report on Friday, March 20th. Cantor Fitzgerald restated an &#34;overweight&#34; rating on shares of Annexon in a research report on Wednesday, January 14th. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Annexon in a research note on Monday, April 20th. Finally, Wall Street Zen raised Annexon from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $17.00.</p>
<div class="lb-trans"><p>其他几位研究分析师最近也对该股票发表了看法。Chardan Capital 在 3 月 20 日星期五的报告中重申了对 Annexon 的 “买入” 评级，并给出了 16.00 美元的目标价。Cantor Fitzgerald 在 1 月 14 日星期三的研究报告中重申了对 Annexon 的 “增持” 评级。Weiss Ratings 在 4 月 20 日星期一的研究报告中重申了对 Annexon 的 “卖出（d-）” 评级。最后，Wall Street Zen 在周六的报告中将 Annexon 的评级从 “卖出” 上调至 “持有”。五位股票研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，共识目标价为 17.00 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on Annexon</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Annexon 的最新研究报告</strong></p>
</div><h2>Annexon Price Performance</h2>
<div class="lb-trans"><h2>Annexon 价格表现</h2>
</div><p>NASDAQ ANNX opened at $5.69 on Monday. The company's 50 day simple moving average is $5.69 and its two-hundred day simple moving average is $5.08. Annexon has a 1 year low of $1.60 and a 1 year high of $7.18. The stock has a market capitalization of $932.25 million, a PE ratio of -4.66 and a beta of 1.22.</p>
<div class="lb-trans"><p>纳斯达克 ANNX 周一开盘价为 5.69 美元。该公司的 50 日简单移动平均为 5.69 美元，200 日简单移动平均为 5.08 美元。Annexon 的一年低点为 1.60 美元，一年高点为 7.18 美元。该公司的市值为 9.3225 亿美元，市盈率为 -4.66，贝塔值为 1.22。</p>
</div><p>Annexon (NASDAQ:ANNX - Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.07.</p>
<div class="lb-trans"><p>Annexon（纳斯达克：ANNX - 获取免费报告）最近于 5 月 7 日星期四发布了季度财报。该公司报告的每股收益为（0.23 美元），超过了市场普遍预期的（0.30 美元）7 美分。</p>
</div><h2>Insider Transactions at Annexon</h2>
<div class="lb-trans"><h2>Annexon 内部交易</h2>
</div><p>In related news, EVP Michael Overdorf sold 6,225 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $5.10, for a total value of $31,747.50. Following the transaction, the executive vice president owned 124,464 shares of the company's stock, valued at $634,766.40. This represents a 4.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through the SEC website. Also, CFO Jennifer Lew sold 7,851 shares of the firm's stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $5.11, for a total value of $40,118.61. Following the sale, the chief financial officer owned 113,765 shares in the company, valued at $581,339.15. The trade was a 6.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 32,513 shares of company stock worth $165,973. Company insiders own 12.67% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，执行副总裁 Michael Overdorf 于 2 月 18 日星期三出售了 6,225 股该股票。该股票的平均售价为 5.10 美元，总价值为 31,747.50 美元。交易后，该执行副总裁持有 124,464 股公司股票，价值 634,766.40 美元。这代表其持股比例减少了 4.76%。该交易已在证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站获取。此外，首席财务官 Jennifer Lew 于 2 月 18 日星期三出售了 7,851 股公司的股票。该股票的平均售价为 5.11 美元，总价值为 40,118.61 美元。出售后，首席财务官持有 113,765 股公司股票，价值 581,339.15 美元。该交易使其持股比例减少了 6.46%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去的九十天里，内部人士共出售了价值 165,973 美元的 32,513 股公司股票。公司内部人士持有公司股票的 12.67%。</p>
</div><h2>Hedge Funds Weigh In On Annexon</h2>
<div class="lb-trans"><h2>对 Annexon 的对冲基金看法</h2>
</div><p>A number of hedge funds and other institutional investors have recently modified their holdings of ANNX. AQR Capital Management LLC increased its position in shares of Annexon by 122.6% during the 1st quarter. AQR Capital Management LLC now owns 73,790 shares of the company's stock valued at $142,000 after purchasing an additional 40,637 shares during the last quarter. Jane Street Group LLC lifted its position in Annexon by 8.2% in the 1st quarter. Jane Street Group LLC now owns 99,924 shares of the company's stock worth $193,000 after buying an additional 7,553 shares during the last quarter. Acadian Asset Management LLC lifted its position in Annexon by 31.1% in the 1st quarter. Acadian Asset Management LLC now owns 203,990 shares of the company's stock worth $393,000 after buying an additional 48,345 shares during the last quarter. Geode Capital Management LLC boosted its stake in Annexon by 1.8% in the second quarter. Geode Capital Management LLC now owns 2,284,773 shares of the company's stock worth $5,484,000 after buying an additional 39,763 shares in the last quarter. Finally, American Century Companies Inc. grew its position in Annexon by 6.6% during the second quarter. American Century Companies Inc. now owns 211,195 shares of the company's stock valued at $507,000 after acquiring an additional 13,001 shares during the last quarter.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近修改了对 ANNX 的持股。AQR Capital Management LLC 在第一季度将其在 Annexon 的持股增加了 122.6%。AQR Capital Management LLC 目前持有 73,790 股公司股票，价值 142,000 美元，此前在上个季度购买了 40,637 股。Jane Street Group LLC 在第一季度将其在 Annexon 的持股增加了 8.2%。Jane Street Group LLC 目前持有 99,924 股公司股票，价值 193,000 美元，此前在上个季度购买了 7,553 股。Acadian Asset Management LLC 在第一季度将其在 Annexon 的持股增加了 31.1%。Acadian Asset Management LLC 目前持有 203,990 股公司股票，价值 393,000 美元，此前在上个季度购买了 48,345 股。Geode Capital Management LLC 在第二季度将其在 Annexon 的持股增加了 1.8%。Geode Capital Management LLC 目前持有 2,284,773 股公司股票，价值 5,484,000 美元，此前在上个季度购买了 39,763 股。最后，American Century Companies Inc. 在第二季度将其在 Annexon 的持股增加了 6.6%。American Century Companies Inc. 目前持有 211,195 股公司股票，价值 507,000 美元，此前在上个季度购买了 13,001 股。</p>
</div><h2>Annexon Company Profile</h2>
<div class="lb-trans"><h2>Annexon 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company's research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.</p>
<div class="lb-trans"><p>Annexon Inc 是一家临床阶段的生物技术公司，专注于针对神经退行性和神经免疫疾病患者的补体靶向疗法的发现和开发。该公司的研究平台以抑制 C1 复合物为中心，C1 复合物是经典补体途径的关键启动因子，涉及多种罕见且危及生命的疾病。通过选择性地靶向上游补体激活，Annexon 旨在防止异常的免疫介导损伤，这种损伤是吉兰 - 巴雷综合症（GBS）和自身免疫性神经病等疾病的特征。</p>
</div><p>At the core of Annexon's pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.</p>
<div class="lb-trans"><p>Annexon 的管线核心是 ANX005，这是一种针对 C1q 亚单位的人源化单克隆抗体，目前正在进行急性 GBS 和慢性神经退行性疾病的二期临床试验。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Annexon</li>
<li>Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong Momentum</li>
<li>Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players</li>
<li>Flutter Sees Post-Earnings Boost as FanDuel Shows Signs of Recovery</li>
<li>3 Healthcare Stocks Set to Benefit From the One Big Beautiful Bill</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Annexon</li>
<li>超越 NVIDIA：强劲势头的 Picks-and-Shovels AI 投资</li>
<li>量子财报季正在升温——关注两大主要参与者</li>
<li>Flutter 在财报后看到提升，FanDuel 显示复苏迹象</li>
<li>3 只医疗保健股票将从一项重大法案中受益</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5OWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=ANNX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Annexon Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Annexon 吗？</h2>
</div><p>Before you consider Annexon, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Annexon 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Annexon wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Annexon 并不在名单上。</p>
</div><p>While Annexon currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Annexon 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

HC Wainwright 对 Annexon 2030 财年的收益预期持乐观态度